These findings suggested that concomitant use of a glinide, α-GI, and/or a DPP-4 inhibitor enable tight control of postprandial hyperglycemia in patients with GC-DM without the need for insulin injection therapy. This evidence concerns the gene INS and diabetes mellitus.